BMS sues over generic of blockbuster leukaemia treatment
04-10-2021
BMS boosts cardio portfolio with $13bn buy
06-10-2020
FDA approves Dr Reddy’s Vascepa generic
13-08-2020
Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
Katherine Welles / Shutterstock.com
Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bristol Myers Squibb, BMS, Celgene, Dr Reddy’s, Revlimid, lenalidomide, generics, settlement, cancer, oncology
